Drugs / Favezelimab/Pembrolizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06395090 | Jan 2025 → Jun 2029 | metastatic neoplasm | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Favezelimab/Pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06395090 ↗ |
| Route | Intravenous | “via an IV infusion Q3W” NCT06395090 ↗ |